A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Phase 1
- Conditions
- Astrocytoma, Grade IVGlioblastoma
- Interventions
- Drug: EGFR(V)-EDV-Dox
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Engeneic Pty Limited
- Target Recruit Count
- 20
- Registration Number
- NCT02766699
- Locations
- 🇺🇸
Lenox Hill Hospital, Northwell Health, New York, New York, United States
🇺🇸John Hopkins Hospital, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath